Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

909.44 +90.67 (+11.07%)

Delayed Quote Updated: 12:59 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

67 68 Next >

Regeneron Announces Investor Conference Presentations

April 20, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

1 Cash-Heavy Stock with Promising Prospects and 2 We Find Risky

April 20, 2026

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...

Via StockStory

3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗

April 18, 2026

This once-beaten-down pharma stock remains an intriguing turnaround story.

Via The Motley Fool

Could AbbVie Crash Lilly's Weight‑Loss Party? ↗

April 14, 2026

AbbVie is making progress in this market, but it is still far behind the leader.

Via The Motley Fool

The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026

April 13, 2026

As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an...

Via Finterra

Telix and Regeneron Announce Strategic Radiopharma Collaboration

April 13, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Regeneron and Telix Announce Strategic Radiopharma Collaboration

April 13, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

April 13, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron (REGN): Buy, Sell, or Hold Post Q4 Earnings?

April 10, 2026

Over the past six months, Regeneron has been a great trade, beating the S&P 500 by 32.3%. Its stock price has climbed to $767, representing a healthy 35.8% i...

Via StockStory

Topics Stocks

Productivity Surge and Falling Jobless Claims: The New U.S. Labor Paradigm

April 06, 2026

The United States labor market is currently defying traditional economic gravity, showcasing a resilient "low-hire, low-fire" dynamic that has left analysts and investors recalibrating their...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation

April 03, 2026

By Financial Research Feature April 3, 2026 Introduction In the high-stakes arena of global biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has long stood as a paragon of scientific...

Via Finterra

Topics Economy Intellectual Property World Trade

Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

April 02, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

April 02, 2026

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...

Via StockStory

Topics Government Stocks World Trade

EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)

April 02, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500...

Via MarketMinute

Topics Economy Intellectual Property Stocks

Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena ↗

March 30, 2026

Could Regeneron Pharmaceuticals be the next big winner in biotech? Join us as we break down the company's strengths, challenges, and future potential in this insightful episode.

Via The Motley Fool

Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly

March 27, 2026

INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing...

Via MarketMinute

AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results

March 27, 2026

AstraZeneca (NASDAQ: AZN) shares climbed 2.7% in early trading today, March 27, 2026, following the release of highly anticipated Phase 3 clinical trial results for its latest respiratory blockbuster...

Via MarketMinute

Topics Intellectual Property

Is Regeneron a Multimillionaire-Maker Stock? ↗

March 27, 2026

It's an extremely high bar for any company.

Via The Motley Fool

Topics Intellectual Property

Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment

March 26, 2026

On March 26, 2026, Kodiak Sciences (Nasdaq: KOD) saw its shares ignite, surging 19% in heavy trading following the announcement of overwhelmingly positive topline results from its Phase 3 GLOW2 study....

Via MarketMinute

The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH

March 26, 2026

On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)...

Via Finterra

Topics Economy Initial Public Offering

Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026

March 25, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

March 24, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗

March 20, 2026

This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.

Via The Motley Fool

Is Eli Lilly's Weight Loss Empire in Trouble? ↗

March 13, 2026

It won't be easy to knock the company off its pedestal.

Via The Motley Fool

3 Profitable Stocks We Think Twice About

March 13, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making ↗

March 12, 2026

Regeneron's science and its Dupixent revenue are paving the way for it to further expand its portfolio.

Via The Motley Fool

Topics Earnings

Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

March 09, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Underrated Weight Loss Stocks to Buy Now ↗

March 08, 2026

These companies have a lot more to offer than their prospects in the weight loss market.

Via The Motley Fool

Topics Intellectual Property

1 Nasdaq 100 Stock to Consider Right Now and 2 We Brush Off

March 05, 2026

While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining dema...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

67 68 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.